Eating Disorders News and Research

Latest Eating Disorders News and Research

Study: Women with anorexia draw themselves with prominently different characteristics

Women suffering from anorexia or bulimia draw themselves with prominently different characteristics than women who do not have eating disorders and who are considered of normal weight. This has been revealed in a new joint study from the University of Haifa, Soroka University Medical Center and Achva Academic College, Israel, published in The Arts in Psychotherapy.

14 Feb 2011

Urocortin system plays central role in regulating stress responses

Post-traumatic stress disorder can affect soldiers after combat or ordinary people who have undergone harrowing experiences. Of course, feelings of anxiety are normal and even desirable - they are part of what helps us survive in a world of real threats. But no less crucial is the return to normal - the slowing of the heartbeat and relaxation of tension - after the threat has passed.

9 Feb 2011

Study reveals Facebook users may face risk of developing eating disorders

The same has been found with regard to exposure to music and fashion on the Internet, and to harmful programs on TV. The study also reveals that the risk of developing eating disorders in adolescent girls is moderated when there is more parental supervision over viewing habits.

8 Feb 2011

Phase II results of VELCADE in patients with aggressive lymphoma published in Journal of Clinical Oncology

Millennium: The Takeda Oncology Company today announced that Phase II results of a clinical trial examining VELCADE (bortezomib) in patients with previously untreated aggressive lymphoma were published in the Journal of Clinical Oncology.

5 Feb 2011

GSA commends '2010 Dietary Guidelines for Americans'

The Gerontological Society of America (GSA) - the nation's largest interdisciplinary organization devoted to the field of aging - commends the federal government's recent release of the "2010 Dietary Guidelines for Americans" and particularly applauds its inclusion of specific advice for older adults.

4 Feb 2011

Cognitive behavioral therapy more effective than antidepressant medications for bulimia nervosa

A new evidence report by ECRI Institute comparing the effectiveness of various treatments for bulimia nervosa indicates that cognitive behavioral therapy is more effective than antidepressant medications and supportive therapies in improving eating disorder symptoms.

2 Feb 2011

Baxter launches OLIMEL emulsion for parenteral nutrition

Baxter International today announced the launch of OLIMEL emulsion for infusion in Canada at the American Society of Parenteral and Enteral Nutrition's Clinical Nutrition Week.

From Baxter International Inc. 31 Jan 2011

Study examines link between media consumption, eating disorders among adolescent girls in Fiji

For parents wanting to reduce the negative influence of TV on their children, the first step is normally to switch off the television set. But a new study suggests that might not be enough. It turns out indirect media exposure, i.e., having friends who watch a lot of TV, might be even more damaging to a teenager's body image.

7 Jan 2011

Research provides new insights into eating disorders in Native Americans

The research, published in the International Journal of Eating Disorders, provides new insights into the extent to which Native American populations experience eating disorders, revealing that women are more likely to report behavioral symptoms then men, while challenging views that NA men and ethnically white men will experience different psychological symptoms.

7 Jan 2011

Way of experiencing internal state of body influences perception of body from the outside

A new study, led by Dr Manos Tsakiris from Royal Holloway, University of London, suggests that the way we experience the internal state of our body may also influence how we perceive our body from the outside, as for example in the mirror. The research appears today (5 January) in the Proceedings of the Royal Society B.

5 Jan 2011

Celgene announces regulatory submissions for blood cancer therapies REVLIMID and ISTODAX

Celgene International Sàrl announced regulatory submissions for its blood cancer therapies REVLIMID (lenalidomide) and ISTODAX (romidepsin).

5 Jan 2011

Vicus initiates VT-122 Phase 2 trial in advanced liver cancer, systemic inflammation and cachexia

Vicus Therapeutics, LLC, today announced the initiation of a Phase 2 trial evaluating VT-122, a novel investigational combination of etodolac and propranolol, and Nexavar® (sorafenib) tablets, as a potential new treatment option for patients with advanced liver cancer (hepatocellular carcinoma), systemic inflammation and cachexia.

28 Dec 2010

Fat or obese – What’s in a name?

The question of whether the term ‘fat’ is more appropriate than ‘obese’ was raised in an Australian study that confirmed the former is the “lesser of two evils”. The study from University of NSW study which looked at public perceptions surrounding these words has found that, while both are unwelcome, obese was viewed more negatively.

13 Dec 2010

Alkermes announces preliminary results from ALKS 33 Phase 2 study in alcohol dependence

Alkermes, Inc. today announced preliminary results from a phase 2 clinical study of ALKS 33, one of Alkermes' proprietary candidates for the treatment of reward disorders and other central nervous system (CNS) disorders. The 12-week study was designed to assess the safety and efficacy of daily oral administration of three different dose levels of ALKS 33 compared to placebo in 400 alcohol dependent patients.

9 Dec 2010

Data from comparative REVLIMID study in multiple myeloma presented at 52nd ASH

Celgene International Sàrl today announced that data from a randomised clinical study conducted by the Eastern Cooperative Oncology Group (ECOG) were presented at the 52nd Annual Meeting of the American Society of Hematology comparing REVLIMID® (lenalidomide) plus low-dose dexamethasone (Rd) to lenalidomide plus high-dose dexamethasone (RD) in both younger and older newly-diagnosed multiple myeloma patients (NDMM).

7 Dec 2010

Pivotal Phase II study data of romidepsin in relapsed PTCL presented at ASH 2010

Celgene International Sàrl today announced that data from a pivotal Phase II, multicenter, international, open-label study of romidepsin (ISTODAX) in progressive or relapsed PTCL following prior systemic therapy were presented at the 52nd American Society of Hematology Annual Meeting.

6 Dec 2010

Study: REVLIMID and dexamethasone for high-risk smoldering multiple myeloma reduce risk of disease progression

Celgene International Sàrl (NASDAQ: CELG) announced that data evaluating combination therapy REVLIMID® (lenalidomide) and dexamethasone in patients with high-risk asymptomatic smoldering multiple myeloma were presented during the American Society of Hematology's annual meeting. The study reported REVLIMID and dexamethasone prolonged time to progression.

6 Dec 2010

Investigational study data of REVLIMID with rituximab or rituximab-containing regimen in CLL patients presented at ASH

Celgene International Sàrl announced that clinical data from two investigational studies evaluating the use of REVLIMID (lenalidomide) either with rituximab or following a rituximab-containing regimen in patients with chronic lymphocytic leukaemia were presented at the 52nd American Society of Hematology annual meeting.

6 Dec 2010

Zometa improves OS, PFS in newly diagnosed multiple myeloma patients: Phase III study

A newly published study in the Lancet suggested that a first-line treatment regimen including Zometa (zoledronic acid) significantly improved overall survival and progression-free survival in newly diagnosed multiple myeloma patients compared with a regimen that included oral clodronate. The impact on survival was independent of the effect of Zometa on bone complications (also known as skeletal-related events or SREs).

4 Dec 2010

European Commission approves Pfizer's SUTENT for pancreatic neuroendocrine tumors

Pfizer Inc. announced today that the European Commission has approved SUTENT (sunitinib malate) for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumors (NET) with disease progression in adults.

2 Dec 2010

Eating Disorders News and Research

Latest Eating Disorders News and Research

Study: Women with anorexia draw themselves with prominently different characteristics

Urocortin system plays central role in regulating stress responses

Study reveals Facebook users may face risk of developing eating disorders

Phase II results of VELCADE in patients with aggressive lymphoma published in Journal of Clinical Oncology

GSA commends '2010 Dietary Guidelines for Americans'

Cognitive behavioral therapy more effective than antidepressant medications for bulimia nervosa

Baxter launches OLIMEL emulsion for parenteral nutrition

Study examines link between media consumption, eating disorders among adolescent girls in Fiji

Research provides new insights into eating disorders in Native Americans

Way of experiencing internal state of body influences perception of body from the outside

Celgene announces regulatory submissions for blood cancer therapies REVLIMID and ISTODAX

Vicus initiates VT-122 Phase 2 trial in advanced liver cancer, systemic inflammation and cachexia

Fat or obese – What’s in a name?

Alkermes announces preliminary results from ALKS 33 Phase 2 study in alcohol dependence

Data from comparative REVLIMID study in multiple myeloma presented at 52nd ASH

Pivotal Phase II study data of romidepsin in relapsed PTCL presented at ASH 2010

Study: REVLIMID and dexamethasone for high-risk smoldering multiple myeloma reduce risk of disease progression

Investigational study data of REVLIMID with rituximab or rituximab-containing regimen in CLL patients presented at ASH

Zometa improves OS, PFS in newly diagnosed multiple myeloma patients: Phase III study

European Commission approves Pfizer's SUTENT for pancreatic neuroendocrine tumors

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Eating Disorders News and Research

Latest Eating Disorders News and Research

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in